MAIA
HEALTHCAREMAIA Biotechnology Inc
$1.35-0.04 (-2.88%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving MAIA Today?
No stock-specific AI insight has been generated for MAIA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.87$3.19
$1.35
Fundamentals
Market Cap$82M
P/E Ratio—
EPS$-0.70
Dividend Yield—
Dividend / Share—
ROE-7.5%
Profit Margin—
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding60.7M
MAIA News
20 articles- MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung CancerYahoo Finance·Apr 16, 2026
- MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer TherapyYahoo Finance·Apr 8, 2026
- MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung CancerYahoo Finance·Mar 31, 2026
- Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)Yahoo Finance·Mar 27, 2026
- MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common StockYahoo Finance·Mar 4, 2026
- MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common StockYahoo Finance·Mar 3, 2026
- MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Mar 2, 2026
- MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy MarketYahoo Finance·Feb 24, 2026
- MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth MomentumYahoo Finance·Jan 20, 2026
- MAIA Biotechnology Board Members Continue to Participate in Private Placement FinancingsYahoo Finance·Dec 24, 2025
- MAIA Biotechnology Announces $1.51 Million Private PlacementYahoo Finance·Dec 16, 2025
- MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial InitiatesYahoo Finance·Dec 11, 2025
- MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung CancerYahoo Finance·Dec 11, 2025
- MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout PotentialYahoo Finance·Dec 11, 2025
- MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting ApproachYahoo Finance·Dec 10, 2025
- MAIA Biotechnology Announces Open Market Purchases by CEO and DirectorsYahoo Finance·Dec 1, 2025
- MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025Yahoo Finance·Nov 21, 2025
- MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and InnovationYahoo Finance·Nov 20, 2025
- MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 27, 2025
- MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung CancerYahoo Finance·Oct 23, 2025
All 20 articles loaded
Price Data
Open$1.36
Previous Close$1.39
Day High$1.44
Day Low$1.36
52 Week High$3.19
52 Week Low$0.87
52-Week Range
$0.87$3.19
$1.35
Fundamentals
Market Cap$82M
P/E Ratio—
EPS$-0.70
Dividend Yield—
Dividend / Share—
ROE-7.5%
Profit Margin—
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding60.7M
About MAIA Biotechnology Inc
MAIA Biotechnology Inc. is a pioneering biotechnology firm dedicated to advancing cancer therapies that enhance patient outcomes across multiple cancer types. Leveraging its proprietary technology platforms, the company focuses on developing innovative drug candidates that utilize the immune system to effectively target tumors, addressing significant unmet needs in oncology. With a robust pipeline and a strategic vision for therapeutic innovation, MAIA is positioned to be a key player in the biopharmaceutical industry, poised to capitalize on growth opportunities in the expanding healthcare market.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—